Q-omics provides the consensus-scored AMELY profile across patient tissues and cancer cell-line models. AMELY expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, AMELY is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, AMELY protein abundance shows 27,724 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, KICH, and LSCC as cancer lineages where AMELY shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AMELY — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AMELY survival associations across molecular data types. AMELY RNA expression shows survival associations in the most cancer types (7), followed by mutation status (1) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AMELY RNA expression–survival associations across cancer types. High AMELY expression shows unfavorable associations in KIRC, LIHC, TGCT, STAD and SARC, but favorable associations in BLCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .010). Together, the overview and detailed table identify BLCA as the clearest survival context for AMELY RNA expression.
This table summarizes AMELY tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for AMELY. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AMELY shows lower tumor expression in KICH, KIRC, KIRP, THCA and ESCA and higher tumor expression in PRAD. The KICH box plot shows higher AMELY RNA expression in normal versus tumor tissue (log2 FC = −0.643, t-test p < 0.001).
This table shows molecular features associated with AMELY in patient tissues and cancer cell lines. In patient samples, AMELY shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, AMELY RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
